

Research Letter

Remote Patient Monitoring Use Among Commercially Insured Adults With Cancer

Joseph H Joo^{1,2,3}, MD, MS; Changchuan Jiang^{1,2}, MD, MPH; Jessica I Billig^{2,4}, MD, MSc; Nadia Lieu^{1,2}, MS; Shining Yang^{1,2}, MA; Yujia Jin¹, MS; Arthur S Hong^{1,3}, MD, MPH; Joshua M Liao^{1,2,3}, MD, MSc

¹Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, United States

²Program on Policy Evaluation and Learning, Dallas, TX, United States

³Department of Health Economics, Systems, and Policy, University of Texas Southwestern Medical Center, Dallas, TX, United States

⁴Department of Plastic Surgery, University of Texas Southwestern Medical Center, Dallas, TX, United States

Corresponding Author:

Joseph H Joo, MD, MS

Department of Internal Medicine

University of Texas Southwestern Medical Center

5323 Harry Hines Blvd

Dallas, TX, 75390

United States

Phone: 1 (214) 648 3111

Email: Joseph.Joo@UTSouthwestern.edu

Abstract

Our study describes the characteristics of remote patient monitoring use among commercially insured patients with cancer from 2019 to 2023.

(*JMIR Cancer* 2026;12:e84788) doi: [10.2196/84788](https://doi.org/10.2196/84788)

KEYWORDS

remote patient monitoring; oncology; cancer; commercially insured; utilization

Introduction

Remote patient monitoring (RPM) enables continuous monitoring of vital signs, including temperature, heart rate, and blood pressure. By capturing this information while patients are at home or in their communities, RPM can detect early disease status changes and treatment-related adverse events and potentially improve outcomes through early intervention [1]. As such, RPM holds substantial promise for cancer treatment. In particular, RPM can support timely interventions to facilitate earlier recognition of decompensation, including fever and hypoxia. In the United States, however, outside of several single-centered trials, data on RPM use among patients with cancer are very limited in oncology [2,3]. Therefore, the aim of our nationwide study was to describe the characteristics of RPM use among commercially insured patients with cancer.

Methods

We used 2019-2023 Merative MarketScan commercial claims, which contain longitudinal commercial insurance claims in the United States. The claims included nearly 40 million unique

patients in the outpatient setting for the study period. We used Current Procedural Terminology codes (99091, 99453, 99454, 99457, 99458) to identify RPM services and International Classification of Diseases, Tenth Revision, Clinical Modification codes to identify patients with cancer. Cancer types were classified per American Cancer Society classifications and stratified by the cancer status (active vs history of cancer) [4]. Patients were included if they received RPM and were enrolled in insurance at least 11 out of 12 months in a calendar year.

We described the number and characteristics of patients with cancer with respect to age, sex, region, clinical complexity (ie, Charlson Comorbidity Index) and insurance plan type (health maintenance organization vs preferred provider organization vs other) [5]. We also assessed the total number of months of RPM use and the average number of months of RPM use per patient.

Because of deidentified claims data, the study was determined to be nonhuman research and therefore exempt from institutional review board at the University of Texas Southwestern Medical Center.

Results

Between 2019 and 2023, RPM was used on 236 patients (Table 1). Half of our sample were 55-64 years old (118/236, 50.0%) and located in the southern region of the United States (117/236, 49.6%), with considerable clinical complexity (106/236, 44.9% with a Charlson Comorbidity Index of 4+). Over half of patients receiving RPM were female (141/236, 59.7%). The plurality of patients was enrolled in a preferred provider organization (89/236, 37.7%), followed by high-deductible health (64/236, 27.1%) and health maintenance organization (39/236, 16.5%) plans.

Among the 236 patients, 86.9% (205/236) used RPM for one year, while 13.1% (31/236) used RPM for 2 or more years.

These patients accrued a total of 611 total months of RPM, equating to approximately 2.6 months of RPM use per patient. Of all the RPM use in patients with cancer, 45.7% (448/981) of RPM use was from those with other cancers (ie, cancer of unknown primary, rare cancers, cancer subtypes, and pre-cancers), followed by patients with cancers of the blood and lymph system (122/981, 12.4%) and patients with breast cancer (121/981, 12.3%). RPM was also used among patients with digestive (79/981, 8.1%), reproductive (77/981, 7.9%), urinary (46/981, 4.7%), endocrine (36/981, 3.7%), lung and chest (30/981, 3.1%), and skin cancers (15/981, 1.5%). RPM was least frequently used among patients with bone and soft tissue cancer (1/981, 0.1%), brain and nervous system cancer (3/981, 0.3%), and head and neck cancer (3/981, 0.3%)

Table 1. Characteristics of the patients with cancer using remote patient monitoring (RPM).

	Patients using RPM in 2019-2023 (N=236), n (%)	Patients using RPM for 1 year (n=205), n (%)	Patients using RPM for 2 or more years (n=31), n (%)
Age (y)			
18-34	21 (8.9)	21 (10.2)	0 (0)
35-44	32 (13.6)	28 (13.7)	4 (12.9)
45-54	64 (27.1)	56 (27.3)	8 (25.8)
55-64	118 (50)	99 (48.3)	19 (61.3)
>64	1 (0.4)	1 (0.5)	0 (0)
Sex			
Female	141 (59.7)	115 (56.1)	26 (83.9)
Male	95 (40.3)	90 (43.9)	5 (16.1)
Region			
South	117 (49.6)	101 (49.3)	16 (51.6)
West	45 (19.1)	41 (20)	4 (12.9)
North Central	35 (14.8)	34 (16.6)	1 (3.2)
Northeast	39 (16.5)	29 (14.1)	10 (32.3)
Insurance			
High deductible	64 (27.1)	59 (28.8)	5 (16.1)
Health maintenance organization	39 (16.5)	33 (16.1)	6 (19.4)
Preferred provider organization	89 (37.7)	77 (37.6)	12 (38.7)
Other ^a	38 (16.1)	31 (15.1)	7 (22.6)
Missing	6 (2.5)	5 (2.4)	1 (3.2)
Charlson Comorbidity Index score			
0-1	60 (25.4)	50 (24.4)	10 (32.3)
2-3	70 (29.7)	62 (30.2)	8 (25.8)
4+	106 (44.9)	93 (45.4)	13 (41.9)

^aOther insurance includes basic/major medical plan, comprehensive plan, exclusive provider organization plan, noncapitated (non-cap) point-of-service plan, and capitated (cap) or partially capitated (part cap) point-of-service plan.



Discussion

In this nationwide US study, RPM use was limited to less than 1% (236/6,437,829) of patients with cancer and focused on particular patient groups. These exploratory findings offer several implications for future work.

First, our finding that RPM in the cancer setting was used more in older female patients reflects findings from prior noncancer studies that also showed female patients between the ages of 45 and 64 years to engage most with their clinicians through RPM [6,7]. Future research should evaluate facilitators and barriers to RPM use among younger patients with cancer, particularly given increases in early-onset cancer in the United States and likely greater familiarity with digital interventions such as RPM. Further work is needed to better understand why nearly half of the patients with RPM use were in the south region.

Second, our findings reflect uneven RPM use across cancer types, with disproportionately higher use among other cancers group (cancers of unknown primary, rare cancers, cancer subtypes, and pre-cancers) over other types such as blood and lymph system cancer. Considering that urinary, breast, lung, and digestive cancers are the most common cancer diagnoses in the United States, more work is needed to evaluate the

appropriateness and impact of such findings [8]. Because not only different types of cancer but also the stages of treatment (eg, in remission, undergoing chemotherapy/radiation, postsurgery) could largely impact the indications for RPM use, future research must inform clinicians and policymakers which patients with cancer could most benefit from RPM.

Third, our finding that a patient used RPM for an average of 2.6 months indicates that RPM use is still nascent in the cancer setting. In contrast to more RPM use in chronic diseases such as hypertension (with one study showing patients using RPM about 9 months), there is a dearth of evidence for longitudinal RPM use in cancer [9,10]. Future research is needed to evaluate the outcomes associated with RPM use to better motivate implementation among health systems.

Study limitations included descriptive design and inability to evaluate the associations between RPM use with cancer outcomes. Although RPM use in cancer could have been more prevalent through clinical trials, which are not captured in our study, the goal of our analysis was to assess real-world adoption within commercial claims data. Furthermore, our study does not capture adoption in patients with public health insurances. Ultimately, our results provide early evidence of opportunity to increase RPM use and potentially fruitful areas for future research and implementation.

Acknowledgments

We attest that no artificial intelligence–assisted technologies were used in the writing, editing, or preparation of this manuscript.

Funding

This research protocol was funded by the University of Texas Southwestern National Institutes of Health Clinical and Translational Science Award grant 1U54TR002361.

Data Availability

The datasets generated or analyzed during this study are not publicly available due to data use and licensing restrictions from Merative MarketScan Commercial Database but are available from the corresponding author on reasonable request. The dataset analyzed during this study is the Merative MarketScan Commercial Database, which is one of the largest repositories of commercial claims data available. MarketScan is a registered trademark of Merative Corporation in the United States.

Authors' Contributions

Conceptualization: JHJ, JML

Data curation: SY, YJ

Formal analysis: SY, YJ

Funding acquisition: JML

Investigation: JHJ, JML

Methodology: JHJ, CJ, JIB, ASH, JML

Project administration: JHJ, JML

Resources: JHJ, JML

Software: SY, YJ

Supervision: JML

Validation: JHJ, JML

Visualization: JHJ, CJ, JIB, NL, SY, YJ, ASH, JML

Writing - original draft: JHJ, CJ, JIB, NL, SY, YJ, ASH, JML

Writing - review & editing: JHJ, CJ, JIB, NL, SY, YJ, ASH, JML

Conflicts of Interest

None declared.

References

1. DeRogatis MJ, Pellegrino AN, Wang N, Higgins M, Dubin J, Issack P, et al. Enhancing recovery and reducing readmissions: the impact of remote monitoring on acute postoperative care in outpatient total joint arthroplasty. *J Orthop. Dec* 2024;58:111-116. [doi: [10.1016/j.jor.2024.06.028](https://doi.org/10.1016/j.jor.2024.06.028)] [Medline: [39114426](https://pubmed.ncbi.nlm.nih.gov/39114426/)]
2. Pritchett JC, Paludo JC, Borah BJ, Haddad TC. Remote patient monitoring to transform management of febrile neutropenia in cancer patients. *NEJM Catalyst. Mar 20, 2024;5(4):1*. [doi: [10.1056/cat.23.0365](https://doi.org/10.1056/cat.23.0365)]
3. Pritchett JC, Borah BJ, Desai AP, Xie Z, Saliba AN, Leventakos K, et al. Association of a remote patient monitoring (RPM) program with reduced hospitalizations in cancer patients with COVID-19. *JCO Oncology Practice. Sep* 2021;17(9):e1293-e1302. [doi: [10.1200/op.21.00307](https://doi.org/10.1200/op.21.00307)]
4. Cancer types. American Cancer Society. URL: <https://www.cancer.org/cancer/types.html> [accessed 2026-02-02]
5. Charlson ME, Carrozzino D, Guidi J, Patierno C. Charlson Comorbidity Index: a critical review of clinimetric properties. *Psychother Psychosom. 2022;91(1):8-35*. [FREE Full text] [doi: [10.1159/000521288](https://doi.org/10.1159/000521288)] [Medline: [34991091](https://pubmed.ncbi.nlm.nih.gov/34991091/)]
6. Adepoju O, Dang P, Nguyen H, Mertz J. Equity in digital health: assessing access and utilization of remote patient monitoring, medical apps, and wearables in underserved communities. *Inquiry. 2024;61:469580241271137*. [FREE Full text] [doi: [10.1177/00469580241271137](https://doi.org/10.1177/00469580241271137)] [Medline: [39323052](https://pubmed.ncbi.nlm.nih.gov/39323052/)]
7. Kirkland E, Schumann SO, Schreiner A, Heincelman M, Zhang J, Marsden J, et al. Patient demographics and clinic type are associated with patient engagement within a remote monitoring program. *Telemed J E Health. Aug 01, 2021;27(8):843-850*. [FREE Full text] [doi: [10.1089/tmj.2020.0535](https://doi.org/10.1089/tmj.2020.0535)] [Medline: [34115942](https://pubmed.ncbi.nlm.nih.gov/34115942/)]
8. Cancer stat facts: common cancer sites. National Cancer Institute: Surveillance, Epidemiology, and End Results Program (SEER Program). URL: <https://seer.cancer.gov/statfacts/html/common.html> [accessed 2026-02-02]
9. Smith W, Colbert BM, Namouz T, Caven D, Ewing JA, Albano AW. Remote patient monitoring is associated with improved outcomes in hypertension: a large, retrospective, cohort analysis. *Healthcare (Basel). Aug 09, 2024;12(16):1583*. [FREE Full text] [doi: [10.3390/healthcare12161583](https://doi.org/10.3390/healthcare12161583)] [Medline: [39201142](https://pubmed.ncbi.nlm.nih.gov/39201142/)]
10. Mahuron K, Esslin P, Sun V. Randomized controlled trial-perioperative telemonitoring of patient-generated health data in gastrointestinal oncologic (GI) surgery: assessing outcomes. *Ann Surg. Jan 01, 2026;283(1):48-56*. [doi: [10.1097/sla.0000000000006724](https://doi.org/10.1097/sla.0000000000006724)]

Abbreviations

RPM: remote patient monitoring

Edited by N Cahill, M Balcarras; submitted 25.Sep.2025; peer-reviewed by I Kudel, T Yu, WW Tarazi; comments to author 17.Nov.2025; revised version received 26.Jan.2026; accepted 27.Jan.2026; published 12.Feb.2026

Please cite as:

Joo JH, Jiang C, Billig JI, Lieu N, Yang S, Jin Y, Hong AS, Liao JM

Remote Patient Monitoring Use Among Commercially Insured Adults With Cancer

JMIR Cancer 2026;12:e84788

URL: <https://cancer.jmir.org/2026/1/e84788>

doi: [10.2196/84788](https://doi.org/10.2196/84788)

PMID:

©Joseph H Joo, Changchuan Jiang, Jessica I Billig, Nadia Lieu, Shining Yang, Yujia Jin, Arthur S Hong, Joshua M Liao. Originally published in *JMIR Cancer* (<https://cancer.jmir.org>), 12.Feb.2026. This is an open-access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in *JMIR Cancer*, is properly cited. The complete bibliographic information, a link to the original publication on <https://cancer.jmir.org/>, as well as this copyright and license information must be included.